Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05161468 · ClinicalTrials.gov registry record · Phase 4
Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain
A Phase 4 study, sponsored by Brooke Army Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT05161468: Clinical Trial Phase 4 study, sponsored by Brooke Army Medical Center.
NCT05161468 is a Phase 4 study that was terminated before completion, run by Brooke Army Medical Center. The registered enrollment target is 34 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05161468, a Phase 4 study, was terminated before completion, sponsored by Brooke Army Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will compare three different treatment injections for the management of acromioclavicular joint dysfunction (ACJ Dysfunction). Patients that consent and enroll will be randomized to receive (1) a corticosteroid injection, (2) an injection of Platelet Rich Plasma, or (3) a Lidocaine injection. Follow-up will occur over a 1 year period.
Primary Outcome
The PROMIS PF-CAT uses a 121-item bank to assess current self-reported capabilities related to physical activities. Like all PROMIS measures, the measure is reported on a T score metric, with a score of 50 aligning with the general population mean and a standard deviation of 10. Higher scores indicate more of the quantity being assessed.
Interventions
- DRUG Corticosteroid Injection
- DRUG Lidocaine injection
- DRUG Protein Rich Plasma(PRP) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 4 |
Why NCT05161468 stopped before completion
NCT05161468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Corticosteroid Injection is the first listed.
NCT05161468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05161468 about?
NCT05161468 is a clinical study titled "Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain". This study will compare three different treatment injections for the management of acromioclavicular joint dysfunction (ACJ Dysfunction). Patients that consent and enroll will be randomized to receive (1) a corticosteroid injection, (2) an injection of Platelet Rich Plasma, or (3) a Lidocaine inject...
What is the current status of trial NCT05161468?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2021-08-12. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT05161468?
The interventions under investigation include: Corticosteroid Injection (DRUG), Lidocaine injection (DRUG), Protein Rich Plasma(PRP) Injection (DRUG).
Who is sponsoring clinical trial NCT05161468?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05161468's enrollment target sits among peer trials
34 1520th of 2000 higher than 473 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI